Director/PDMR Shareholding

16 May 2017 15:00 BST


Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 15 May 2017, it was notified by Pascal Soriot, a Director of the Company, that, on 15 May 2017, Mr Soriot ceased to be beneficially interested in 163,000 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

1   Details of the person   discharging managerial responsibilities / person closely associated  
a)   Name   Pascal Soriot
2   Reason for the   notification  
a)   Position/status       Chief Executive Officer
b)     Initial notification   /Amendment   Initial notification
3   Details of the issuer,   emission allowance market participant, auction platform, auctioneer or   auction monitor  
a)   Name   AstraZeneca PLC
4   Details of the   transaction(s): section to be repeated for (i) each type of instrument; (ii)   each type of transaction; (iii) each date; and (iv) each place where   transactions have been conducted  
a)   Description of the   financial instrument, type of instrument       Identification code Ordinary Shares of   US$0.25 each in AstraZeneca PLC           GB0009895292      
b)     Nature of the   transaction   Gift of shares to family members   for nil consideration
c)   Price(s) and volume(s)     Price(s) Volume(s)
0 163,000
d)   Aggregated information         - Aggregated volume           - Price       Not applicable -   single transaction                              
e)   Date of the   transaction   15 May 2017
f)   Place of the   transaction   London

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit   and follow us on Twitter @AstraZeneca.

Media Enquiries                  
Esra Erkal-Paler   UK/Global   +44 203 749 5638  
Karen Birmingham       UK/Global       +44 203 749 5634      
Rob Skelding       UK/Global       +44 203 749 5821      
Jacob Lund       Sweden       +46 8 553 260 20      
Michele Meixell       US       +1 302 885 2677      
Investor Relations
Thomas   Kudsk Larsen     +44 203 749 5712  
Craig   Marks   Finance, Fixed Income, M&A +44 7881 615 764  
Henry   Wheeler   Oncology +44 203 749 5797  
Mitchell   Chan   Oncology +1 240 477 3771  
Lindsey   Trickett   Cardiovascular & Metabolic   Diseases +1 240 543 7970  
Nick   Stone   Respiratory +44 203 749 5716  
Christer   Gruvris Autoimmunity, Neuroscience &   Infection +44 203 749 5711
US toll free +1 866 381 7277

Adrian Kemp

Company Secretary, AstraZeneca PLC

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links